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Psychostimulant use disorders are serious and escalating problems globally, and methamphetamine (METH) is one of the most addictive psychostimulant drugs of abuse 1 , causing dopaminergic neuronal damage in humans following long-term METH use. 2 METH use disorders result in severe health consequences, including mood disturbances, infectious diseases (e.g., HIV and hepatitis C), cardiovascular complications, oral disease, and death. [3] [4] [5] [6] [7] Currently, there are no FDA-approved drugs for the treatment of METH use disorder.
The vesicular monoamine transporter-2 (VMAT2) plays a major role in mediating the neurochemical and behavioral effects of psychostimulants. 8 VMAT2 is recognized as an important target for the discovery of therapeutics for METH use disorder. 9 Small molecules that modulate VMAT2 function and inhibit the pharmacological effects of METH may prove to be efficacious pharmacotherapies for METH use disorder. In this respect, lobeline (1, Fig.  1 ), the major alkaloid of Lobelia inflata, has been shown to inhibit dopamine (DA) uptake into synaptic vesicles via an interaction with VMAT2. 10, 11 Evaluation of lobeline's effects in clinical trials revealed some minor side-effects, including bitter taste and nausea, likely the result of an action as an antagonist at nicotinic acetylcholine receptors (nAChRs). 12, 13 Another limitation was the short plasma half-life of lobeline (~50 min in rodents), 14 which would require the administration of multiple doses per day to maintain efficacy, and multiple dosing would likely result in diminished compliance.
Our research program set out to identify analogs with enhanced affinity and selectivity for VMAT2. The structure of lobeline was modified to remove the oxygen functionalities, resulting in the symmetrical molecule, lobelane (2, Fig. 1 ). Lobelane exhibited high affinity (K i = 0.045 µM) for inhibition of [ 3 H]DA uptake at VMAT2 with 43-, 35-, and 2.5-fold greater selectivity for VMAT2 relative to DAT, SERT, and hERG respectively. 11, 15, 16, 21 Moreover, lobelane dose-dependently decreased METH self-administration in rats, without decreasing sucrose-maintained responding, revealing behavioral specificity and affording enhanced potential as a novel treatment for METH use disorder. 17 Lobelane was modified further to provide two families of analogs, one based on a 2,6-disubstituted piperidine scaffold and another incorporating a 1,4-disubstituted piperidine scaffold, both of which afforded potent inhibitors of DA uptake at VMAT2. 18, 19 To further evaluate structure activity relationships around these scaffolds, 1,4-diphenethylpiperidine and 1,4-diphenethylpiperazine analogs have been modified to incorporate aromatic fluoroethoxy moieties. Incorporation of fluorine atoms into strategic positions in a drug molecule can improve electronic and metabolic properties. In addition, fluorinated analogs incorporating an 18 F positron-emitting isotope have additional value as potential ligands for positron emission tomography (PET) studies. Also, the substitution of the piperidine moiety with a piperazine moiety in these molecules also may afford improved drug-likeness properties.
Fluoroethoxy-containing 1,4-diphenethylpiperidine derivatives were synthesized starting with benzaldehyde. As illustrated in Scheme 1, a variety of variously substituted benzaldehydes (3) were reacted with 4-picoline (4) via Aldol condensation in acetic anhydride at reflux temperature to afford the corresponding (E)-4-styrylpyridine (5). Compound 5 then was hydrogenated with Adams catalyst (PtO 2 ) in acetic acid under hydrogen gas (50 psi) at room temperature to afford the corresponding 4-phenethylpiperidino intermediate (6) . Intermediate 6 was alkylated with various substituted phenethyl bromides (7) in the presence of K 2 CO 3 in acetonitrile at reflux temperature to yield the corresponding 1,4-diphenethylpiperidine analogs 8a-8k; these compounds were further O-alkylated utilizing ethylfluorotosylate and Cs 2 CO 3 in DMF at reflux temperature to yield the corresponding fluoroethoxy-substituted 1,4-diphenethyl-piperidine derivatives 9a-9k (Scheme-1).
As illustrated in Scheme 2, the fluoroethoxy-substituted 1,4-diphenethylpiperazine derivatives were synthesized starting from 1,4-piperazine. 1,4-Piperazine (10) was reacted with a variety of substituted phenethylbromides (11) in toluene at reflux temperature to afford 1-phenethylpiperazine (12) , which was alkylated with various hydroxyphenethylbromides using K 2 CO 3 in acetonitrile at reflux temperature, to yield the corresponding 1,4-diphenethylpiperazine analogs 14a-14f. These compounds were Oalkylated utilizing ethylfluorotosylate and Cs 2 CO 3 in DMF at reflux temperature to yield the corresponding fluoroethoxy-substituted 1,4-diphenethylpiperazine derivatives 15a-15f (Scheme 2).
All synthesized compounds were fully characterized by 1 H NMR, 13 C NMR and high resolution mass spectral analysis.
Compounds 9a-9k and 15a-15f were evaluated for inhibition of [ 3 H]DA uptake at VMAT2 and DAT, [ 3 H]5-HT uptake at the serotonin transporter (SERT), and affinity for the human ether-ago-go related gene (hERG) channel to determine cardiotoxicity. The results are provided in Table 1 .
For inhibition of VMAT2 function, the [ 3 H]DA uptake assay was conducted using preparations of isolated synaptic vesicles from rat brain. 8, 20 The majority of the analogs exhibited In the 1,4-substituted piperidine series, compounds 9j and 9k are positional isomers. Compound 9k, a 1-(3-fluoroethoxyphenethyl) analog, exhibited 6-fold higher affinity (K i = 0.024 µM) when compared to 9j, the 1-(4-fluoroethoxyphenethyl) analog, in the VMAT2 assay. Ortho-and meta-fluoroethoxylphenyl analogs exhibited generally exhibited greater potency compared to para-fluoroethoxyphenyl analogs. Similarly, in the 1,4-piperazine series, compounds 15a, 15b, and 15c are all positional isomers involving the fluoroethoxyphenyl group. Compound 15a, a 2-fluoroethoxyphenethyl-containing analog, and compound 15b, a 3-fluoroethoxyphenethyl-containing analog, exhibited high affinity for VMAT2 (K i = 0.035 and 0.073 µM, respectively), whereas compound 15c, a 4-fluoroethoxyphenethyl-containing analog, was 8-to 17-fold less potent than its positional isomeric analogs, 15a and 15b. Compound 15d, containing a 2-fluoroethoxyphenethyl moiety, had the highest affinity (K i = 0.014 µM) for VMAT2 in this series of analogs.
Interestingly, 15f, which contains a 4-fluoroethoxyphenethyl moiety, was 32-fold less potent than 15d. Thus, regiospecificity of the aromatic fluoroethoxy substituent plays an important role in influencing the affinity of these inhibitors for VMAT2.
Evaluation of 9a-9k and 15a-15f as inhibitors of [ 3 H]DA uptake at DAT afforded K i values in the range of 1.06-8.38 μM ( Table 1 ), indicating that these compounds have good selectivity for VMAT2 over DAT. In the SERT assay, 20 K i values were in the range of 0.070 µM to 6 μM (Table 1) . Thus, for the majority of the compounds in this series, good selectivity for VMAT2 over SERT also was found. While 15d was the most potent (K i = 0.014 µM) compound in the series as an inhibitor of VMAT2, 15d exhibited 160-fold and 5-fold selectivity for VMAT2 over DAT and SERT, respectively. Thus, 15d was one of the least selective compounds in the series.
Compounds 9a-9k and 15a-15f were evaluated also for affinity at the hERG channel to determine potential cardiotoxicity. 21 Although the majority of the analogs exhibited moderate affinity for hERG (K i = 0.28-0.85 μM), most had at least 10-fold greater selectivity for VMAT2 relative to hERG. However, inclusion of a piperazine ring, rather than a piperidine ring in the scaffold, while having minimal impact on affinity for VMAT2 and DAT (as evidenced in comparing 9j with 15c, and 9k with 15b), resulted in markedly greater selectivity for VMAT2 over SERT and hERG. These findings suggest that the piperazinecontaining scaffold has important advantages with respect to off-target activity (e.g., cardiotoxicity) relative to the piperidine-containing scaffold in the pursuit of potent and selective VMAT2 inhibitors as therapeutics for METH use disorder.
We carried out in silico evaluation of several drug-like and physicochemical properties of the above fluoroethoxy analogs and compared them to those of their parent compounds (i.e. molecules in which the fluoroethoxy moiety has been replaced with a methoxy group) utilizing appropriate predictive algorithms (ACD Profiler Suite); these properties included LogP, water-solubility, pKa, Lipinski compliance, drug-likeness, and ADME profiling (Caco-2, CNS penetration, and human intestinal absorption). The fluoroethoxy-1,4-diphenethylpiperidine and piperazine analogs generally exhibited good lipophilicity with logP values in the range of 5.21-5.80 and 3.91-4.56, respectively, and had moderate to good water-solubility (0.41-6.14 and 0.37-3.70 mg/mL, respectively). The piperidine analogs exhibited pKa values in the range 9.1-9.3, whereas the piperazine analogs had pKa values in the range 7.4-7.8. Lipinski compliance and drug-likeness were moderate (1 violation) for the piperidine analogs and moderate to good (0-1 violations) for the piperazine analogs. The ADME profiling data indicated that both the piperidine and the piperazine analogs were predicted to be highly absorbed (100%) from the human intestine, to be highly permeable in the Caco-2 cell assay, and were classified as CNS penetrants. These data are provided in Tables S1 and S2 in the Supporting Information. Comparison of the above properties of the fluoroethoxy-1,4-diphenethyl piperidine and piperazine analogs with those of their corresponding parent methoxy analogs indicated that replacing the aromatic methoxy substituent with an aromatic fluoroethoxy substituent had little overall effect on these properties.
Compound 15b was considered the lead compound based on its high affinity for VMAT2 and due to it having the greatest selectivity for VMAT2 in the compound series (Fig. 2 , Table 1 ). Compound 15b had a K i value of 0.073 µM for VMAT2 and exhibited 115-, 82-, and 59-fold greater selectivity for VMAT2 compared to DAT, SERT and hERG, respectively. Based on these characteristics, 15b selectively interacts with VMAT2 and is predicted to have low abuse liability and cardiotoxicity.
In Summary, a small library of fluoroethoxy-containing analogs of 1,4-diphenethylpiperidine and 1,4-diphenethylpiperazine were synthesized and evaluated for inhibition of VMAT2 function, as well as for inhibition of DAT and SERT function and interaction with the hERG channel. The parent compound, lobelane, has a high affinity (K i = 0.045 µM) for VMAT2 with 43-, 35-, and 2.5-fold greater selectivity relative to DAT, SERT, and hERG respectively. Most of the compounds tested in this study exhibited affinity for VMAT2 (K i <0.075 µM), similar to lobelane.
Most of the compounds tested in this study exhibited affinity for VMAT2 (K i <0.075 μM), similar to lobelane. However, many of the compounds exhibited improved selectivity for VMAT2 relative to DAT (45-to 160-fold), SERT (46-to 161-fold), and hERG (11-to 156-fold). Generally, the piperazine and piperidine scaffolds confer affinity at VMAT2 similar to lobelane, while improving selectivity over off target proteins. Notably, the piperazine scaffold may be beneficial for reducing cardiotoxicity.
Compound, 15d exhibited the highest affinity (K i = 0.014 μM) at VMAT2 relative to the other compounds in the series; however, 15d was not selective for VMAT2, exhibiting only 5-fold greater selectivity for VMAT2 versus SERT. Among the compounds in this series, 15b was the most selective compound for VMAT2, with good affinity (K i = 0.073 µM) at VMAT2 and 115-, 82-, and 59-fold greater selectivity for VMAT2 relative to DAT, SERT, and hERG, respectively. In particular, it was observed that the piperazino analogs generally exhibited lower affinity for the hERG channel when compared to their piperidino counterparts.
Compound 15b is considered the lead compound from this series of analogs due to its nanomolar affinity at VMAT2, as well as its >60-fold selectivity for VMAT2 over other the off target proteins. Currently, 15b is being investigated further for in vivo activity in preclinical models of METH self-administration as a potential treatment for METH use disorder.
Cs 2 CO 3 (0.91 mmol) were added at ambient temperature. Reaction mixtures were heated at 120°C for 6 h. After completion of the reactions (monitored by TLC), reaction mixtures were diluted with water and extracted with dichloromethane (2 × 30 mL). Organic layers were dried over Na 2 SO 4 and concentrated under reduced pressure to afford crude products. Crude products were purified by column chromatography (silica gel, 3-5% methanol in dichloromethane) to afford pure products (yield 65-70%). These products were further converted to HCl salts by treatment with a 2M HCl solution in diethyl ether.4-(3-(2-fluoroethoxy)phenethyl)-1-phenethylpiperidine hydrochloride (9a) 1 56 (m, 2H), 1.39-1.33 (m, 3H) ppm. 13 C NMR (CD 3 OD, 100 MHz) δ 160.1, 145.4, 140.4, 130.4, 129.6, 129.6, 127.4, 122.2, 115.8, 112.7, 84.0, 82.3, 68.5, 68.3, 61.2,  54.5, 39.1, 35.7, 33.9, 33.3, 32.2 
